Probius
PrivateLast Round
Debt
Aug 26, 2025
Total Funding Raised
$20.93M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Probius operates in Healthcare & Life Sciences and is based in Fremont, California. Its latest recorded funding round was a Debt round in August 2025.
Probius is a biotechnology research company developing a deep-tech platform that combines quantum sensing and artificial intelligence for biochemical analysis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Drug Discovery, Sensors, Medical AI
Business Model
B2B
Customer Profile
Hardware + Subscription, Subscription SaaS, Usage-Based SaaS, Hardware Sales, Services & Consulting
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Probius Comparables
Compare Probius with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nautilus Biotechnology | 73% | |
| Seer | 70% | |
| Quantum-Si | 68% |
For institutional investors. Book with your work email.
Probius Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Aug 26, 2025 | ||||
| Series A | Oct 19, 2022 | ||||
| Grant | Jun 15, 2020 | ||||
| Seed | Dec 3, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Probius Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cota Capital | Series A |
| StartX | Seed |
| Baidu Ventures | Series A |
| TSV Capital | Seed |
| Joyance Partners | Seed |
| Defense Advanced Research Projects Agency | Grant |
| Shanda Group | Seed, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 197% MoM, reaching 1.6K.
- Jul 25, 2026
Monthly visitors grew 181% MoM, reaching 543.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 18, 2026
Probius is developing new tools for biomedical analysis and diagnostics that combine AI with its Quantum Electrochemical Spectroscopy platform to analyze complex biological-sample data.
- is_developingSep 18, 2026
Probius continues developing its AI-enabled approach to TB screening with a $1.48 million Bill & Melinda Gates Foundation grant for low-resource and underserved populations, while the technology remains under development.
For institutional investors. Book with your work email.
Probius Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Probius's valuation, stock price, and market status.
Is Probius a public or private company?
Probius is a private company.
What is the current stock price of Probius?
Probius is a private company, so its shares have no public market price. Caplight tracks Probius's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Probius worth (valuation)?
Valuation information for Probius is not publicly available.
Can I buy Probius stock?
Probius shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Probius's last funding round?
Probius's most recent funding round was Debt on August 26, 2025.
Who are the main investors in Probius?
Key investors in Probius include Cota Capital.
Will Probius IPO soon?
No public IPO plans have been announced for Probius.
How can I track Probius secondary market activity?
Caplight tracks bids, offers, and trades in Probius's shares on secondary markets.